WHO ICTRP trial
Bortezomib and Bendamustine in the Treatment of Refractory/Relapsed Multiple…
EUCTR2005-003843-30-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-003843-30-DE |
|---|---|
| Public title | Bortezomib and Bendamustine in the Treatment of Refractory/Relapsed Multiple Myeloma |
| Scientific title | Bortezomib and Bendamustine in the Treatment of Refractory/Relapsed Multiple Myeloma |
| Primary sponsor | ORTHO BIOTECH, Division of JANSSEN-CILAG GmbH |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Germany |
| Conditions | Cytologically and/or histologically established multiple myeloma requiring treatment, stage II or III (Salmon and Durie). 1. - 3. Relapse or progression with measurable myeloma protein in the blood or urine following chemotherapy or… |
| Interventions | Trade Name: Velcade 3,5 mg Pulver zur Herstellung einer Injektionslösung Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Bortezomib CAS Number: 179324-69-7 Other descriptive name: Boronic acid… |
| Registration date | Sep 26, 2005 |
| Target size | 44 |
| Secondary IDs | 26866138MMY2029 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: